logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Gilead Sciences Inc.
(GILD)
Veklury (remdesivir)
The company said data from three retrospective studies of the real-world treatment with remdesivir in patients hospitalized with COVID-19 showed reduction in mortality rate.
-
-
06/22/2021
Tonix Pharmaceuticals Holding Corp.
(TNXP)
TNX-102 SL
The company said it plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome or Post-Acute Sequelae of COVID-19 (PASC).
Pre-IND meeting with the FDA is scheduled for third quarter 2021
-
06/22/2021
Vir Biotechnology
(VIR)
Sotrovimab
Announced positive results from the Phase 3 study dubbed COMET-ICE. Treatment with sotrovimab significantly reduced the risk of hospitalization or death among high-risk adult outpatients with mild-to-moderate COVID-19.

U.S. National Institutes of Health (NIH) updated its COVID-19 treatment guidelines to recommend use of sotrovimab.
-
GlaxoSmithKline plc
06/22/2021
BioVaxys Technology Corp.
CoviDTH
BioVaxys received positive response from the FDA for pre-investigative new drug review for CoviDTH clinical development.
Written response from the FDA is expected by July 23, 2021.

In vivo animal safety study of CoviDTH to start in July.
-
06/15/2021
PBG BioPharma Inc.
Antiviral therapeutic for Covid-19
PBG BioPharma plans to develop a phytochemical based, broad-spectrum anti-viral plant isolate to combat viral infections including the SARS-CoV-2 coronavirus.
-
-
06/08/2021
Altimmune Inc.
(ALT)
AdCOVID
New results from the preclinical study of AdCOVID showed its neutralizing ability against SARS-CoV-2 B.1.351 variant that originated in South Africa.
-
University of Alabama at Birmingham
05/27/2021
RedHill Biopharma Ltd.
(RDHL)
Opaganib
The company received patent protection for opaganib as method for treatment of Covid-19 from the U.S. Patent and Trademark Office (USPTO)
-
-
05/27/2021
RedHill Biopharma Ltd.
(RDHL)
RHB-107
The company received patent protection for RHB-107 (upamostat) as method for treatment of Covid-19 from the U.S. Patent and Trademark Office (USPTO)
-
-
05/27/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa (dabigatran etexilate) oral blood thinning medication for children. Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth. The only other approved blood thinning medication for children is given by injection. Amazon.com Inc.'s two-day Prime Day event is happening now with more than 2 million deals on offer. The e-commerce giant's biggest shopping extravaganza of the year started June 21 at 3 a.m. EDT and runs for 48 hours, through June 22. Prime Day 2021 will feature the largest number of deals ever offered in the seven year history of the Prime Day Celebrations. New deals are being launched throughout The European Commission announced Tuesday that it has opened a formal antitrust investigation to assess whether Google has violated EU competition rules by favoring its own online display advertising technology services in the so called "ad tech" supply chain, to the detriment of competing providers...